Abstract
Apixaban, marketed under the brand name Eliquis, is a direct oral anticoagulant (DOAC) used for preventing and treating various thromboembolic disorders. Developed by Bristol-Myers Squibb and Pfizer, it has been widely adopted due to its ease of use and effectiveness compared to traditional anticoagulants like warfarin. This paper provides a comprehensive overview of apixaban, including its chemical properties, development history, market presence, competition, and the impact of generics. The paper also speculates on the sales performance of the drug from 2020 to 2024 based on available data and trends.
Keywords
Apixaban, Eliquis, direct oral anticoagulant, chemical properties, market analysis, global sales, generics.
Introduction
Apixaban is a direct factor Xa inhibitor that works by blocking the action of factor Xa, an enzyme crucial for blood clotting. By inhibiting this enzyme, apixaban prevents the formation of blood clots. Approved by the U.S. Food and Drug Administration (FDA) in 2012, it is used for a variety of indications, including stroke prevention in atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism (PE), and other thromboembolic disorders. As a direct oral anticoagulant (DOAC), apixaban offers several advantages over older medications like warfarin, including a predictable pharmacokinetic profile and no requirement for routine monitoring.
Chemical Properties
Apixaban has the chemical formula C25H25ClN8O4 and a molar mass of approximately 490.98 g·mol−1. It is a small molecule with a complex structure that includes a chloro group, a thiophene ring, and an oxazolidine core. Its IUPAC name is 5-chloro-N-{[2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]oxazolidin-5-yl]methyl}thiophene-2-carboxamide. This design allows apixaban to selectively inhibit factor Xa, offering effective anticoagulation therapy with minimal bleeding risk compared to traditional drugs like warfarin.
Development and Approval Timeline
Apixaban was co-developed by Bristol-Myers Squibb and Pfizer. The drug was first approved by the European Medicines Agency (EMA) in 2011 and by the FDA in December 2012. Eliquis quickly became one of the most widely prescribed DOACs worldwide, benefiting from its strong clinical trial evidence, including the ARISTOTLE trial, which demonstrated its superior safety and efficacy compared to warfarin. Its approval has expanded over the years to include indications such as the treatment and prevention of deep vein thrombosis and pulmonary embolism.
Time on the Market
Apixaban has been available for over a decade, with its initial launch in 2012. Since then, the drug has established itself as a leader in the DOAC market due to its predictable dosing regimen, minimal food and drug interactions, and the absence of routine monitoring. Eliquis has become a significant player in the global anticoagulant market, especially for patients with atrial fibrillation, a condition that is prevalent in the aging global population.
Global Sales and Market Competition
Apixaban has consistently been one of the top-selling drugs in the world. In 2022, Eliquis generated $9.5 billion in global sales, contributing significantly to both Bristol-Myers Squibb and Pfizer's pharmaceutical revenues. The market for anticoagulants is large and growing, driven by the increasing prevalence of cardiovascular diseases and an aging population.
The competition in the DOAC space includes rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Savaysa). While these drugs are all factor Xa inhibitors or thrombin inhibitors, apixaban's superior safety profile in clinical trials, particularly in preventing strokes in patients with atrial fibrillation, has helped it maintain a strong market presence.
Generics and Related Developments
Apixaban’s patent was set to expire in 2026 in the United States, though generic versions are already available in some markets outside of the U.S., such as the EU. The introduction of generics has made apixaban more affordable in those regions, increasing accessibility for patients. However, in markets like the U.S., Eliquis remains a dominant brand, and the generic competition is expected to intensify as patents expire in the coming years.
Speculated Sales Figures (2020–2024)
While exact sales numbers for each year are not publicly available, based on available data and trends, the following estimates can be made:
2020: $7.5 billion
The global pandemic likely impacted elective procedures, but apixaban's stable use for chronic conditions like atrial fibrillation likely helped maintain solid sales.
2021: $8.0 billion
With the gradual recovery from COVID-19 and continued strong demand for stroke prevention, sales increased steadily.
2022: $9.5 billion
Eliquis continued to benefit from the expansion of its indications and widespread use in managing atrial fibrillation and thromboembolic disorders.
2023: $10.0 billion
As more markets saw generic competition for other DOACs, Eliquis maintained its position as a leader in the market, bolstered by high demand in the U.S. and Europe.
2024: $9.8 billion
A slight dip due to generic competition in some markets is expected, but Eliquis will remain a major player in the anticoagulant market.
Conclusion
Apixaban has revolutionized anticoagulation therapy, providing an effective alternative to warfarin and becoming one of the top-selling drugs globally. Its chemical design, ease of use, and strong clinical trial results have made it a preferred choice for both healthcare providers and patients. While generic versions of apixaban are becoming available in some markets, Eliquis remains a dominant player, and its revenue is expected to stay robust in the coming years, despite increasing competition.
Active Pharmaceutical Ingredient
503612-47-3
Apixaban, (chemical grade, purity ≥99.0%) are currently supplied by our company. [Own compliance factory, fully support factory audit] For details, you can call the bottom line to get the latest price of the product!
Disclaimer:Products are only available to countries where there is no valid patent protection. Products still covered by patents rights are available exclusively for experimental or registration purpose pursuant to national applicable law, and shall be sold in strict accordance with the laws of the People's Republic of China and the laws of the Buyer's country. All products are not for human use. Buyer is obligated for evaluation of the patent situation in its domestic market and shall be held liable for uses which do not fall within the scope of the experimental or registration use exception and are not permitted by national applicable law.
References
Apixaban. (n.d.). In Wikipedia. Retrieved from https://en.wikipedia.org/wiki/Apixaban
Pfizer Annual Report 2022. (2022). Retrieved from https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2022/performance
Eliquis – Drug Information. (2021). In PubChem. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Apixaban
Anticoagulants Market Growth Report. (2023). In Grand View Research. Retrieved from https://www.grandviewresearch.com/industry-analysis/anticoagulants-market-report
other information:
FDA、Wikipedia、Chatgpt、DeepSeek、chemicalbook
If there is any infringement, please apologize and delete. If there are any errors, welcome to criticize and correct.
Under no circumstances shall the information or opinions expressed herein be construed as investment advice for any person.
International Department:
Copyright(C)2018 Anqing Chico Pharmaceutical Co., Ltd.
Supported byChinaChemNet
